v3.26.3
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jul. 29, 2026
Nov. 04, 2025
Nov. 03, 2022
Sep. 30, 2026
Sep. 30, 2025
Jun. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Aug. 31, 2026
Mar. 31, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Share purchase value         $ 5,694,000 $ 2,441,000        
Exercise price       $ 10.66     $ 10.66   $ 0.01  
Share based compensation       $ 100,000 $ 200,000   $ 200,000 $ 300,000    
Restricted Stock Units (RSUs) [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Vesting period             5 years      
2013 Beyond Air Equity Incentive Plan [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Stock option shares authorized for issuance       84,000     84,000      
Number of shares available for grant         44,897     44,897    
Vesting period             4 years      
Expiration period             10 years      
Weighted average fair value of options granted             $ 7.48      
2013 Beyond Air Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Weighted average remaining service period             6 months      
2013 BA Plan [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Share based compensation             $ 200,000      
2013 BA EquityIncentivePlan [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Weighted average remaining service period             1 year 3 months 18 days      
Unrecognized stock-based compensation expense       $ 700,000     $ 700,000      
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Stock option shares authorized for issuance     4,000,000              
Number of shares available for grant       1,771,250     1,771,250      
Vesting period             4 years      
Weighted average remaining service period             1 year      
Expiration period             10 years      
Number of additionl shares reserve for issuance     2,000,000              
Unrecognized stock-based compensation expense       $ 100,000     $ 100,000      
2023 Neuro Nos Ltd Equity Incentive Plan [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Stock option shares authorized for issuance                   1,725,000
Number of shares available for grant       466,149     466,149      
Vesting period             4 years      
Weighted average remaining service period             6 months      
Expiration period             10 years      
Unrecognized stock-based compensation expense       $ 100,000     $ 100,000      
Common Stock [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Share purchase value [1]                
Shares available for resale [1]         93,854 28,235        
January 2026 Pre-Funded Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Stock issued during the period, shares             107,131      
July 2026 Pre-Funded Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Stock issued during the period, shares             436,443      
Purchase Agreement [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Share purchase value   $ 20,000,000                
Shares available for resale   80,000         320,304      
Common stock minimum purchase amount   $ 25,000                
Beneficial ownership limitation percentage   4.99%                
Price per share       $ 5.47     $ 5.47      
Adjustments in additional paid in capital             $ 1,800,000      
Offering price       $ 5.47     $ 5.47      
Securities urchase Agreement [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Placement agent commissions $ 700,000                  
Securities urchase Agreement [Member] | Common Stock [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Number of shares sold 167,011                  
Securities urchase Agreement [Member] | Pre-funded Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Number of shares sold 1,638,835                  
Offering price $ 5.66                  
Gross proceeds $ 10,200,000                  
Exercise price $ 0.0001                  
Securities urchase Agreement [Member] | Series A Common Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Number of shares sold 1,805,846                  
Securities urchase Agreement [Member] | Series B Common Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Number of shares sold 1,805,846                  
Securities urchase Agreement [Member] | Common Stock and Common Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Gross proceeds $ 9,100,000                  
Other offering costs $ 400,000                  
Securities urchase Agreement [Member] | Common Stock and Common Warrants [Member] | Investors [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Offering price $ 5.66                  
Securities urchase Agreement [Member] | Common Stock and Common Warrants [Member] | Directors and Executive Officers [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Offering price 5.76                  
Securities urchase Agreement [Member] | Common Warrants [Member]                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                    
Exercise price $ 5.51                  
[1] Prior period results have been adjusted to reflect the one-for-twenty reverse stock split in July 2026. See Note 1, Organization and Business for details.